Press Releases

  • Apr. 9, 2013 biOasis’s Update on the BT2111-Herceptin® Program

    Vancouver, British Columbia–(Business Wire)– biOasis Technologies Inc. (TSX:V.BTI) announced today an update on the advancement of its anti-cancer product candidate BT2111. BT2111 is a brain- penetrating conjugate of trastuzumab (Herceptin®) and our Transcend vector designed to treat brain metatastsis of HER2+ breast cancer. Based on the exceptional data announced on February 7th of this year,… Read more »

  • Feb. 13, 2013 biOasis named to 2013 TSX Venture 50®

    Vancouver, British Columbia–(Business Wire)– biOasis Technologies Inc. (TSX:V.BTI) announces it has been named one of the 2013 TSX Venture 50® companies. The 2013 TSX Venture 50® includes the top 10 companies in 5 major industry sectors that have been identified as leaders in providing shareholder value on Canada’s junior stock exchange. “We are very proud… Read more »

  • Feb. 7, 2013 biOasis Announces Positive Anti-Tumour Efficacy Data

    biOasis Transcend-Herceptin® Conjugate (BT2111) Significantly Reduces the Number and Size of Metastatic HER2+ Breast Cancer Tumors in the Brain

  • Dec. 14, 2012 biOasis Technologies Year in Review 2012

    Vancouver, B.C.–(Business Wire)– biOasis Technologies Inc. (TSX:V.BTI) today is pleased to provide a 2012 year in review. biOasis has come a long way in 2012. The company has enjoyed a steady, measured progression towards its goals in the execution of its science and business objectives. Through 2012 the company developed a powerful network of highly… Read more »

  • Dec. 3, 2012 biOasis Enters Into a Research Collaboration Agreement with UCB

    Vancouver, B.C.–(Business Wire)– biOasis Technologies Inc. (TSX:V.BTI) announced today that it has entered into a research collaboration agreement with Brussels, Belgium-based UCB (Euronext Brussels: UCB), to evaluate biOasis’s Transcend technology in the area of the delivery of therapeutic compounds to the brain. In connection with this agreement, biOasis will conduct certain experiments to provide UCB… Read more »

  • Nov. 14, 2012 biOasis Enters Into a Research & Evaluation Agreement with MedImmune

    Vancouver, B.C.–(Business Wire)– biOasis Technologies Inc. (TSX:V.BTI) announced today that it has entered into a research and evaluation agreement with MedImmune (MedImmune), the global biologics arm of AstraZeneca. Under the terms of this collaboration, biOasis will conduct certain experiments at MedImmune’s expense with the objective of demonstrating that biOasis’s Transcend technology can deliver to the… Read more »

  • Sep. 27, 2012 Experienced Life Science Executive Joins biOasis Board of Directors

    Vancouver, B.C.–(Business Wire)– biOasis Technologies Inc. (BTI) is pleased to announce that Mr. Gregory Gubitz has joined the Board of Directors of the Company. Mr. Gubitz is a seasoned life science executive and lawyer, with significant transaction and investment experience. Mr. Gubitz was most recently Senior Vice President, Corporate Development and General Counsel of Biovail… Read more »

  • Sep. 24, 2012 biOasis Receives Preliminary Histopathology (Tissue Toxicity) Results On Its Herceptin® BT2111 Program

    Vancouver, B.C.–(Business Wire)– biOasis Technologies Inc. (TSX:V.BTI) announces today positive results of a preliminary toxicity evaluation of test animals that formed part of its xenograft model study, the results of which were announced September 5, 2012. That study showed that BT211, biOasis conjugate of trastuzumab (Herceptin®) designed to treat brain metatastsis of HER2+ breast cancer… Read more »

  • Sep. 5, 2012 biOasis’s Herceptin®-BT2111 Stops Human Breast Cancer Tumor Growth in Animals

    Vancouver, B.C.–(Business Wire)– biOasis Technologies Inc. (TSX:V.BTI) announced today that a key animal study in its BT2111 oncology program, showed that BT2111, biOasis’ conjugate of trastuzumab (Herceptin®) designed to treat brain metatastsis of HER2+ breast cancer, arrests the growth tumors in a xenograft model of human breast carcinoma. The human tumor xenograft model is accepted… Read more »

  • Aug. 28, 2012 2012-2013 Board of Directors election, Officers appointment and Option Grant

    Vancouver, B.C.–(Business Wire)– biOasis Technologies Inc. (TSX: V BTI) announces its board of directors elected by the shareholders at its Annual General Meeting held today: Robin HutchisonDavid Clark,CADr. Terry PearsonDr. Chris FibigerMichael Hutchison Q.C.Ron EricksonGreg Gubitz The Board also appointed the following officers of the Company: Robin Hutchison, President and CEODavid Clark, Chief Financial Officer… Read more »